Advertisement

Topics

"Time Limited Eating In Adolescents With Diabetes (Time LEAD): A Pilot Study∨derfield=date∨derval=DESC" News Stories

16:54 EDT 16th July 2019 | BioPortfolio

Here are the most relevant search results for "Time Limited Eating In Adolescents With Diabetes (Time LEAD): A Pilot Study∨derfield=date∨derval=DESC" found in our extensive news archives from over 250 global news sources.

More Information about Time Limited Eating In Adolescents With Diabetes (Time LEAD): A Pilot Study∨derfield=date∨derval=DESC on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Time Limited Eating In Adolescents With Diabetes (Time LEAD): A Pilot Study∨derfield=date∨derval=DESC for you to read. Along with our medical data and news we also list Time Limited Eating In Adolescents With Diabetes (Time LEAD): A Pilot Study∨derfield=date∨derval=DESC Clinical Trials, which are updated daily. BioPortfolio also has a large database of Time Limited Eating In Adolescents With Diabetes (Time LEAD): A Pilot Study∨derfield=date∨derval=DESC Companies for you to search.

Showing "Time Limited Eating Adolescents With Diabetes Time LEAD" News Articles 1–25 of 21,000+

Tuesday 16th July 2019

Puma Biotechnology’s Licensing Partner Knight Therapeutics Receives Regulatory Approval from Health Canada to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of Hormone Receptor Positive, HER2-Positive Early Stage Breast Cancer

Neratinib becomes the first anti-HER2 treatment to be approved in Canada, as extended adjuvant therapy for women with early stage HR-positive, HER2-positive breast cancer following adjuvant trastuzumab-based therapy. Treatment with neratinib in the approved Health Canada indication resulted in a 51% reduction in the risk of invasive disease recurrence or death at 2 years versus placebo after p...


NextGen Healthcare Partners with Appriss Health to Combat Substance Use Disorder

Enhanced prescription capabilities in NextGen Office will help prevent the illegal acquisition of controlled substances from multiple sources NextGen Healthcare, Inc. (NASDAQ:NXGN), the leading provider of ambulatory-focused technology solutions, announced today that it has integrated

Senseonics Announces Public Offering of Common Stock

Senseonics Holdings, Inc. (“Senseonics”) (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it has commenced a registered underwritten public offering of $25.0 million of its shares of common stock. In addition, Senseonics anti...


Senseonics Announces Commencement of Convertible Notes Offering

Senseonics Holdings, Inc. (“Senseonics” or the “Company”) (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the commencement of an offering of $80.0 million aggregate principal amount of 5.25% convertible senior notes due 2025 ...

Nautilus, Inc. Powers Up Bowflex Brand with New Agency Partner FIG

Nautilus, Inc. (NYSE: NLS), a leader in innovative fitness equipment, has named FIG as its creative agency for the company’s iconic Bowflex® brand. FIG will handle advertising and creative campaign executions, including TV, social and digital. Bringing on a creative agency is part of the company’s long-term strategy to reenergize the flagship Bowflex brand, which offers premium home gyms, ...

Fitbit Schedules Q219 Financial Results for July 31, 2019

Fitbit (NYSE: FIT), the leading global wearables brand, today announced that it expects to release results for its second quarter 2019 on Wednesday, July 31, after market close. In conjunction with a press release, management will host a conference call at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time that afternoon. A live webcast of the conference call will be available on the Investor sectio...

Gilead Sciences to Release Second Quarter 2019 Financial Results on Tuesday, July 30, 2019

-- Conference Call and Webcast to Follow -- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2019 financial results will be released on Tuesday, July 30, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the second quarter 2019 and provide a business update. The live...

Senseonics Holdings, Inc. Reports Preliminary Second Quarter 2019 Net Revenue

Preliminary second quarter net revenue between $4.4M and $4.7M Nearly 4,500 Eversense® System prescriptions written in the U.S. as of June 30, 2019 Expanded commercial coverage to 76M lives as of June 30, 2019 Senseonics Holdings, Inc. (“Senseonics” or “Company”) (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, im...

Seattle Genetics Reports Second Quarter 2019 Financial Results

-Record ADCETRIS® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $159.0 Million in the Second Quarter, an Increase of 30 Percent Over the Second Quarter of 2018- -Biologics License Application Submitted to FDA for Enfortumab Vedotin to Treat Advanced or Metastatic Urothelial Cancer Based on Results from the EV-201 Pivotal Trial- -Topline Results from Tucatinib HER2CLIMB Pivotal Trial ...

Scientists have retrieved the full genome of HIV-1 from a 1966 sample. It confirms the virus hopped over from chimpanzees some time in the early 1900s. https://www.statnews.com/2019/07/16/hiv-genetic-code-extracted-evidence-virus-emergence/ …

Scientists have retrieved the full genome of HIV-1 from a 1966 sample. It confirms the virus hopped over from chimpanzees some time in the early 1900s. https://www.statnews.com/2019/07/16/hiv-genetic-code-extracted-evidence-virus-emergence/ …

Healthy Lifestyle May Reduce Dementia Risk

Healthful eating and exercise might lower dementia risk in those who are genetically predisposed to developing Alzheimer’s disease.

Amare Heart2Heart Mental Wellness Symposium to Feature Elizabeth Smart for Keynote

Amare’s Second Annual Heart2Heart Mental Wellness Symposium Will Include Special Speakers Elizabeth Smart and Author Steve Farber IRVINE, Calif. (PRWEB) July 16, 2019 Amare Global’s second annual Heart2Heart Mental Wellness Symposium will take place this September 5–7, 2019, at the Hilton Anaheim, CA. This annual event from The Mental Wellness Company® will feature motivating speeches,...

Neurotoxicity of Synthetic Cannabinoids Versus Cannabis in Adolescents

Neuropsychiatric effects from synthetic cannabinoids were more severe than those from cannabis in this multicenter case registry study of adolescents presenting to the emergency department.

Comprehensive Reconciliation Support by a PSAO Partner Means More Money for Pharmacies, More Time for Customers

Issues related to claims reconciliation emerge as a pain point for owners of independent pharmacies as they manage their business. Because reimbursement errors can be common, timely and accurate reconciliation is key to ensuring full payments. The ability to reconcile each claim drives better visibility into contract performance, which in turn drives profitability. However, many community pharmac...

It is time to enforce FMD compliance, says European Medicines Verification Organisation

The body that runs the Falsified Medicines Directive says medicines regulators in individual countries should begin enforcing its compliance.

Frelii, Inc. Opens its First Subsidiary in Canada

Frelii, Inc. (OTC PINK: FRLI) (“Frelii” or “the Company") has opened a new wholly owned subsidiary, Frelii Canada Inc. in Mississauga, Ontario, Canada, making it the Company’s first subsidiary supporting the Lehi, Utah headquarters. Frelii Canada will be led by Sandy Uppal, Chief Administrative Officer at Frelii and supported by Yvan Aubin, Executive Vice President of Finance at Frelii. ...

Reproductive Care Center to Award Free IVF Treatment in Maybe Baby Contest

Reproductive Care Center (RCC) and 97.1 ZHT are teaming up to award one lucky couple a free Multi-Cycle IVF treatment with their "Maybe Baby" contest. The contest will begin on July 1st, 2019, with the selected couple being awarded on September 23. The "Maybe Baby" contest is an excellent opportunity for those living with infertility to open up to their family and friends about...

The Economic Tsunami of Liver Disease: Echosens Publishes New White Paper, Highlights Impact on U.S. Financial Solvency

Free White Paper Download Here Echosens, a high-technology company offering the FibroScan family of products, today announces the release of its white paper

Boehringer looks to oncology vaccines with €325m acquisition

Boehringer takes on AMAL to gain access to its cancer vaccine technology, with a lead candidate due to enter first-in-human studies this month.

Removing #Anthrax Bacterial Armor May Lead to New Therapies: http://ow.ly/ZCgs50v1QjK pic.twitter.com/QfCkcilH1u

Removing #Anthrax Bacterial Armor May Lead to New Therapies: http://ow.ly/ZCgs50v1QjK  pic.twitter.com/QfCkcilH1u

Samples taken from the Arctic show rising and falling levels of lead over two millennia. #ResearchHighlight https://go.nature.com/2JxUUZU 

Samples taken from the Arctic show rising and falling levels of lead over two millennia. #ResearchHighlight https://go.nature.com/2JxUUZU 

LC GC® Hosts Educational Webcast on Analytical Method Development

Attendees will gain insights from an industry expert and submit questions in real time LC GC®, a leading multimedia platform of peer-reviewed technical information on the field of chromatography and the separation sciences, will present the webcast “A Practical Guide to Analytical Method Development” Thursday, July 18, at 2 p.m. EDT. “This educational webcast will guide all novice chrom...

NCI Announces Appointment of Charles Hicks as Chief Financial Officer

NCI Information Systems, Inc. (NCI), a leading provider of advanced information technology solutions and professional services to U.S. federal government agencies, today announced Charles (Chuck) Hicks Jr. has joined the company as executive vice president, chief financial officer and treasurer. Hicks brings more than 25 years of industry experience to his role at NCI leading the finance functi...

According to THE SAGE GROUP, the Annual Economic Burden of Critical Limb Ischemia (CLI) in the U.S. Exceeds $200 Billion

A new analysis published by THE SAGE GROUP LLC, concludes that the all-cause cost of CLI exceeds $200 billion. “CLI is an extremely expensive disease,” stated Mary L. Yost, President of THE SAGE GROUP. “Inpatient hospitalizations account for the majority of costs with Medicare paying 73% of the bill.” “Treatment with major amputation is one well-known factor that increases CLI costs...

Boehringer Ingelheim Acquires AMAL Therapeutics, Enhancing its Cancer Immunology Portfolio

Ingelheim am Rhein, Germany and Geneva, Switzerland –  15 July 2019 – Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL’s lead vaccine ATP128 is currently developed for stag...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks